Stockscreener 앱 받기
16.47
7.42%
-1.32
시간 외 거래:
16.75
0.28
+1.70%
전일 마감가:
$17.79
열려 있는:
$18.48
하루 거래량:
27,180
Relative Volume:
0.33
시가총액:
$22.10M
수익:
-
순이익/손실:
$-24.14M
주가수익비율:
-1.1777
EPS:
-13.985
순현금흐름:
$-22.40M
1주 성능:
-1.79%
1개월 성능:
-48.19%
6개월 성능:
+94.91%
1년 성능:
+178.68%
1일 변동 폭
$16.47
$18.59
1주일 범위
$16.43
$19.42
52주 변동 폭
$5.31
$36.76
센세이 바이오테라 Stock (SNSE) Company Profile
명칭
Sensei Biotherapeutics Inc
전화
(240) 243-8000
주소
1405 RESEARCH BLVD, SUITE 125, ROCKVILLE
Compare SNSE vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SNSE
Sensei Biotherapeutics Inc
|
16.47 | 23.87M | 0 | -24.14M | -22.40M | -13.98 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
센세이 바이오테라 Stock (SNSE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-20 | 개시 | Leerink Partners | Outperform |
| 2025-06-02 | 재개 | H.C. Wainwright | Buy |
| 2024-05-14 | 개시 | Stephens | Overweight |
| 2021-07-01 | 다운그레이드 | Berenberg | Buy → Hold |
| 2021-06-29 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2021-03-01 | 개시 | Berenberg | Buy |
| 2021-03-01 | 개시 | Citigroup | Buy |
| 2021-03-01 | 개시 | Oppenheimer | Outperform |
| 2021-03-01 | 개시 | Piper Sandler | Overweight |
모두보기
센세이 바이오테라 주식(SNSE)의 최신 뉴스
Sensei Biotherapeutics Inc. (SNSE) Q1 2026 Earnings: Deep EPS Miss Reflects Heavy R&D Investment and Pre-Revenue StatusDiluted EPS Report - Newser
SNSE Q1 2026 Earnings: EPS Significantly Below Estimates as Company Invests in PipelineCommunity Buy Signals - Newser
SNSE Initiated Coverage by Citigroup -- Rating Set to Buy with $55 Target - GuruFocus
Sensei Biotherapeutics Updates 2026 Board Reconstitution Plans - TipRanks
Sensei Biotherapeutics (SNSE) revises 2026 board reconstitution timeline - Stock Titan
Sensei Biotherapeutics (SNSE) Q1 2026 Earnings: Massive EPS Miss Overshadowed by Upbeat SentimentReal Trader Network - Newser
Sensei Biotherapeutics Acquires Faeth Therapeutics, Raises $200 Million and Issues Series B Preferred Stock Conversion to Common Shares 1 - Minichart
Sensei Biotherapeutics Sets Vote on Series B Conversion - TipRanks
Sensei Biotherapeutics to Convert Series B Preferred, Pro Forma Shows 25.7M Shares and $184.6M Equity - TradingView
$200M financing and Faeth deal reshape Sensei Biotherapeutics (NASDAQ: SNSE) - Stock Titan
SNSE SEC FilingsSensei Biotherapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
How Should Investors Value Sensei Biotherapeutics (SNSE) After Q - GuruFocus
Sensei Biotherapeutics Analyst Ratings and Price Targets | NASDAQ:SNSE - Benzinga
Sensei Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update - BioSpace
Sensei Biotherapeutics stock (US81728A1088): Q1 results and corporate update draw focus - AD HOC NEWS
Is Sensei Biotherapeutics (SNSE) Attractive After Q1 2026? EPS - GuruFocus
Millennium management reports $89k Sensei Biotherapeutics share sales - Investing.com
Millennium management reports $89k Sensei Biotherapeutics share sales By Investing.com - Investing.com South Africa
Millennium entities (SNSE) net sell 12,861 Sensei Biotherapeutics shares - Stock Titan
Sensei Biotherapeutics (SNSE) stake by Millennium entities hits 147,731 shares - Stock Titan
[Form 4] Sensei Biotherapeutics, Inc. Insider Trading Activity - Stock Titan
Millennium entities disclose 127,095 Sensei Biotherapeutics (SNSE) shares - Stock Titan
Sensei Biotherapeutics, Inc. Q1 2026 10-Q Filing: Financial Statements, Risk Factors, and Management Analysis - Minichart
Sensei Biotherapeutics (NASDAQ: SNSE) joint holders report 128,761 shares (9.6%) - Stock Titan
Transformative Quarter for Sensei Biotherapeutics (SNSE) - GuruFocus
Sensei Biotherapeutics Reports Q1 2026 Financial Results, Highlights PIKTOR Clinical Progress and Faeth Acquisition - Minichart
Sensei Biotherapeutics 1Q Research and Development Expenses $18.0M >SNSE - Moomoo
StemPoint (SNSE) and Michelle Ross report 9.9% stake in Sensei - Stock Titan
Sensei Biotherapeutics Releases Q1 2026 Financial Results - AlphaStreet
[SCHEDULE 13G] Sensei Biotherapeutics, Inc. Passive Investment Disclosure (>5%) - Stock Titan
Sensei Biotherapeutics, Inc. 1Q 2026: Net income $(170.2M), EPS $(131.45) — 10-Q Summary - TradingView
SNSE: Faeth acquisition and $200M raise drive pipeline expansion; net loss rises on one-time costs - TradingView
Sensei Biotherapeutics reports $170.2M Q1 net loss, $202.8M cash position - TradingView
Sensei Biotherapeutics (SNSE) absorbs Faeth acquisition, $200M raise and going-concern risk - Stock Titan
Sensei Biotherapeutics (Nasdaq: SNSE) Q1 loss reflects Faeth acquisition impact - Stock Titan
Press Release: Sensei Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update - Moomoo
Sensei Biotherapeutics reports Q1 2026 loss on Faeth charges - grafa.com
"Cold" Solid Tumors Become the Proving Ground for a New Generation of Engager and Immune-Priming Therapies - GlobeNewswire Inc.
TradingKey - TradingKey
Sensei Biotherapeutics Secures 200 Million Dollars for Oncology Pipeline - HarianBasis.co
Sensei Biotherapeutics (SNSE): Best Performing NASDAQ Stocks According to Wall Street Analysts - Insider Monkey
Sensei Biotherapeutics Doses First Patient in Phase 1b/2 Trial of PIKTOR in HR+/HER2- Advanced Breast Cancer - PharmiWeb.com
Sensei Biotherapeutics announces first patient dosed in FTH-PIK-101 trial - TipRanks
The competitive edge that makes Sensei Biotherapeutics (SNSE) special (-3.15%) 2026-05-05Most Discussed Stocks - newser.com
Sensei Biotherapeutics begins trial of PIKTOR in breast cancer By Investing.com - Investing.com South Africa
Sensei Biotherapeutics begins trial of PIKTOR in breast cancer - Investing.com
10 Best Performing NASDAQ Stocks According to Wall Street Analysts - Insider Monkey
Short Selling Surges in Small-Cap Healthcare Stocks Amid Bearish Sentiment - GuruFocus
Sensei Biotherapeutics Inc expected to post a loss of 62 cents a shareEarnings Preview - TradingView
[144] Sensei Biotherapeutics, Inc. SEC Filing - Stock Titan
Sensei Biotherapeutics (SNSE) price target increased by 53.85% to 51.00 - MSN
센세이 바이오테라 (SNSE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.98%
0.12%
자본화:
|
볼륨(24시간):